Federal 340B Overhaul Bill Unlikely This Year

Why It Matters

Without congressional action, the 340B program faces mounting legal and regulatory pressure that could reshape discount availability for safety‑net providers and impact drug pricing dynamics nationwide.

Key Takeaways

• Senate's bipartisan 340B reform group stalled by member turnover
• Draft legislation lacks definition of 340B‑eligible patient, a core drugmaker concern
• Drugmakers file lawsuits and impose data requirements, increasing provider friction
• Providers push back with state laws and court victories, limiting manufacturer actions
• CMS may revisit Medicare 340B payment cuts, adding financial pressure

Pulse Analysis

The 340B drug‑pricing program, which has ballooned from roughly $6.6 billion in 2010 to $81 billion in 2024, remains a flashpoint between safety‑net providers and pharmaceutical manufacturers. A bipartisan Senate “gang of six” began drafting comprehensive reform in early 2024, aiming to balance provider access with industry concerns. However, turnover among the senators—most notably the departure of Sen. Markwayne Mullin to the DHS—has stalled progress, and the draft still omits a clear definition of a 340B‑eligible patient, a linchpin for any meaningful policy change.

Pharmaceutical companies have shifted tactics from legislative lobbying to litigation and administrative pressure. AbbVie filed a lawsuit challenging HRSA’s decades‑old patient definition, arguing it enables excessive discount use. Bristol‑Myers Squibb joined peers in imposing data‑submission mandates on covered entities, prompting providers to decry added costs and revenue erosion. In response, providers have rallied at the state level, with at least 21 states enacting statutes that block manufacturer restrictions on contract pharmacies, and federal courts have largely upheld these protections, though recent appellate splits hint at future legal uncertainty.

Looking ahead, the 340B reform agenda is unlikely to surface in the looming reconciliation bill, given its minimal impact on direct federal spending. Instead, the program may face fiscal headwinds as CMS prepares to revisit Medicare Part B payment cuts for 340B drugs, a move reminiscent of the Trump‑era reductions that were later overturned by the Supreme Court. Hospitals and clinics dependent on 340B discounts must therefore brace for potential revenue shortfalls while monitoring both legislative stalls and evolving regulatory actions that could reshape the program’s financial landscape.